보고서 요약(국문)

보고서 개요
세계 세티리진 염산염 시장은 2023년 67억 9,790만 달러에 달했으며, 2024년부터 2031년까지 연평균 3.4%의 성장률로 2031년에는 88억 8,250만 달러에 이를 것으로 예상됩니다.
세티리진 염산염은 알레르기 반응 시 신체에서 분비되는 화학물질인 히스타민의 작용을 선택적으로 차단하는 2세대 항히스타민제입니다. 히스타민은 표적 세포의 H1 수용체에 결합하여 재채기, 눈 가려움 및 눈물, 콧물, 두드러기 등 전형적인 알레르기 증상을 유발하는 일련의 과정을 촉발합니다.
세티리진은 H1 수용체에 결합하여 히스타민의 작용을 억제함으로써 알레르기 증상을 완화합니다. 1세대 항히스타민제와 비교했을 때, 세티리진은 H1 수용체에 대한 친화도가 더 높고 혈뇌장벽을 통과할 가능성이 낮아 졸음과 같은 중추신경계 부작용이 적습니다.
세티리진은 다양한 알레르기 질환에 폭넓게 적용 가능하고 안전성 프로필이 우수하여 어린아이부터 노인까지 모든 연령대의 환자에게 의료 전문가들이 선호하는 약물입니다.
시장 동향: 주요 동인
알레르기 질환 유병률 증가
전 세계 세티리진 염산염 시장의 수요는 여러 요인에 의해 주도되고 있습니다. 그중 가장 중요한 요인은 알레르기 질환 유병률의 증가입니다. 알레르기성 비염, 습진, 알레르기성 결막염과 같은 알레르기 질환의 증가는 세티리진 시장의 주요 성장 동인입니다.
현재 1억 5천만 명이 넘는 유럽인이 만성 알레르기 질환을 앓고 있습니다. 이 수치는 증가할 것으로 예상되며, 2025년까지 EU 인구의 50% 이상이 알레르기성 비염, 천식, 습진과 같은 질환을 포함한 알레르기로 고통받을 수 있다는 예측이 나오고 있습니다. 알레르기와 이용 가능한 치료법에 대한 대중의 인식이 높아짐에 따라 세티리진에 대한 수요가 증가하고 있습니다. 더 많은 사람들이 알레르기 증상에 익숙해지면서 불편함을 완화하기 위해 효과적인 약물을 찾으려는 경향이 커지고 있습니다.
또한, 업계 주요 기업들이 연구 개발에 더욱 집중하고 있으며, 임상 시험 건수 증가가 이러한 시장 성장을 견인하고 있습니다. 예를 들어, 2024년 1월 UCB는 피부염 환자를 대상으로 Xyzal(레보세티리진)과 Zyrtec(세티리진)의 효능 및 안전성을 비교 평가하는 무작위 3상 임상 연구를 발표했습니다. 이러한 유형의 연구는 피부염 치료에 있어 해당 약물의 효능에 대한 확실한 데이터를 제공하기 때문에 임상 연구에 매우 중요합니다. 피부염은 흔히 피부의 염증, 발적, 가려움증을 특징으로 합니다.
제한 요인
약물과 관련된 부작용 및 이상 반응, 그리고 엄격한 규제 요건과 같은 요인들이 시장 성장을 저해할 것으로 예상됩니다.
시장 세분화 분석
전 세계 세티리진 염산염 시장은 제형, 연령대, 용도, 유통 채널 및 지역별로 세분화됩니다.
정제 부문은 전 세계 세티리진 염산염 시장 점유율의 약 64.3%를 차지했습니다.
정제 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 세티리진 염산염 정제는 알레르기성 비염, 만성 두드러기, 알레르기성 결막염과 같은 다양한 알레르기 질환에 대한 신뢰할 수 있는 치료제로 전 세계 시장에서 중요한 위치를 차지하고 있습니다. 알레르기 유병률 증가와 효과적인 알레르기 관리 전략에 대한 인식 제고는 예측 기간 동안 세티리진 정제에 대한 수요를 지속적으로 증가시킬 것으로 예상됩니다. 또한, 업계 주요 기업들의 파트너십 및 협력과 같은 전략은 시장 성장을 견인하는 데 기여하고 있습니다. 예를 들어, 2023년 8월 중국 국가약품감독관리국(NMPA)은 신화제약(가오미) 유한회사(신화제약의 완전 자회사)에 세티리진 염산염 정제에 대한 추가 승인 신청 승인서를 발급했습니다. 이 승인은 해당 제품이 제네릭 의약품에 요구되는 품질 및 효능 일관성 평가를 성공적으로 통과했음을 의미합니다.
시장 지역별 점유율
북미는 전 세계 세티리진 염산염 시장의 약 43.9%를 차지했습니다.
북미 지역은 알레르기성 비염, 만성 두드러기, 알레르기성 결막염과 같은 알레르기 질환의 증가로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상되며, 이는 이 지역에서 세티리진 염산염에 대한 수요를 촉진하는 주요 요인입니다.

알레르기성 비염은 흔히 건초열로 알려져 있으며, 전 세계 인구의 상당 부분을 차지하는 사람들에게 영향을 미치는 흔한 질환으로, 유병률은 10%에서 30%에 이르는 것으로 추정됩니다. 미국에서도 최근 몇 년 동안 성인과 어린이의 상당수가 계절성 알레르기를 경험했다고 보고했습니다. 미국 질병통제예방센터(CDC) 자료에 따르면, 2021년 미국 성인의 약 25.7%, 어린이의 약 18.9%가 계절성 알레르기를 겪었다고 응답했습니다.
미국 인구에서 알레르기성 비염의 높은 유병률은 재채기, 콧물, 눈 가려움증과 같은 알레르기성 비염의 일반적인 증상을 완화하는 데 효과적인 세티리진과 같은 항히스타민제에 대한 상당한 수요를 창출합니다. 더욱이, 알레르기와 이용 가능한 치료법에 대한 대중의 인식이 높아짐에 따라 세티리진에 대한 수요도 증가하고 있습니다.

또한, 이 지역에서는 주요 기업들의 존재, 잘 발달된 의료 인프라, 그리고 활발한 인수합병이 시장 성장을 견인하고 있습니다. 예를 들어, 2022년 6월, 글렌마크 파마슈티컬스(Glenmark Pharmaceuticals Ltd.)의 완전 자회사인 글렌마크 파마슈티컬스(Glenmark Pharmaceuticals Inc., USA)는 미국 워크하르트(Wockhardt Limited)로부터 여러 일반의약품(OTC)에 대한 승인된 신약 허가 신청(ANDA)을 인수했습니다.
인수된 ANDA에는 위장관 궤양의 치료 및 예방에 사용되는 파모티딘 정제 USP 10mg 및 20mg(OTC), 항히스타민제인 세티리진 염산염 정제 USP 5mg 및 10mg(OTC), 그리고 알레르기성 결막염 및 알레르기성 비염에 사용되는 올로파타딘 염산염 점안액 USP 0.1%(OTC)가 포함됩니다.

시장 세분화
제형별
정제
용액
시럽
연령대별
성인
소아
적용 분야별
알레르기성 비염
알레르기성 결막염
만성 두드러기
습진
기타
유통 채널별
병원 약국
소매 약국
온라인 약국
지역별
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
스페인
이탈리아
기타 유럽
남미
브라질
아르헨티나
기타 남미
아시아 태평양
중국
인도
일본
한국
기타 아시아 태평양
중동 및 아프리카
시장 경쟁 환경
세티리진 염산염 시장의 주요 글로벌 업체로는 Johnson & Johnson Services, Inc., GSK plc, UCB S.A., Teva Pharmaceutical Industries Ltd. 등이 있습니다. 화이자(Pfizer Inc.), 메이저 파마슈티컬스(Major Pharmaceuticals), 시플라(Cipla), 닥터 레디스 래버러토리스(Dr. Reddys Laboratories Ltd.), 애드바케어 파마(AdvaCare Pharma), 아덴 헬스케어(Aden Healthcare) 등이 주요 기업입니다.
주요 개발 사항
2023년 4월, 니콕스(Nicox SA)는 중국 독점 파트너사인 오큐멘션 테라퓨틱스(Ocumension Therapeutics)가 알레르기성 결막염 관련 안구 가려움증 치료를 위한 0.24% 농도의 세티리진 점안액(Zerviate) 신약 허가 신청서(NDA)를 제출했다고 발표했습니다.

보고서 구매 이유
제형, 연령대, 적용 분야, 유통 채널 및 지역별 글로벌 세티리진 염산염 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위함입니다.

트렌드 및 공동 개발 분석을 통해 사업 기회를 식별할 수 있습니다.

모든 세그먼트를 포함한 세티리진 염산염 시장의 다양한 데이터가 담긴 엑셀 시트가 제공됩니다.

PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 결과를 담고 있습니다.
주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑은 Excel 파일로 제공됩니다.
글로벌 세티리진 염산염 시장 보고서는 약 70개의 표, 63개의 그림, 그리고 183페이지 분량으로 구성될 예정입니다.
주요 고객 (2024년 기준)
제조업체/구매자
산업 투자자/투자은행가
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Report Overview
The Global Cetirizine Hydrochloride Market reached US$ 6,797.9 million in 2023 and is expected to reach US$ 8,882.5 million by 2031 growing with a CAGR of 3.4% during the forecast period 2024-2031.
Cetirizine hydrochloride is a second-generation antihistamine that works by selectively blocking the action of histamine, a chemical released by the body during an allergic reaction. Histamine binds to H1 receptors on target cells, triggering a cascade of events that leads to the typical symptoms of allergies such as sneezing, itchy and watery eyes, runny nose, and hives.
By binding to the H1 receptors, cetirizine prevents histamine from exerting its effects, thereby alleviating allergy symptoms. Compared to first-generation antihistamines, cetirizine has a higher affinity for the H1 receptor and is less likely to cross the blood-brain barrier, resulting in fewer central nervous system side effects like drowsiness.
The broad applicability of cetirizine for various allergic conditions, along with its favorable safety profile, has made it a widely preferred option among healthcare providers for patients spanning all age groups, from young children to the elderly.
Market Dynamics: Drivers
Increasing prevalence of allergic diseases
The demand for the global cetirizine hydrochloride market is driven by multiple factors. One of the key factors is the increasing prevalence of allergic diseases. The rise in allergic conditions, such as allergic rhinitis, eczema, and allergic conjunctivitis, is a primary driver for the cetirizine market.
Currently, over 150 million Europeans suffer from chronic allergic diseases. This number is expected to rise, with predictions indicating that by 2025, more than 50% of the EU population could be affected by allergies, including conditions like allergic rhinitis, asthma, and eczema. There is a growing awareness among the public regarding allergies and the available treatment options, which is leading to an increased demand for cetirizine. As more individuals become familiar with the symptoms of allergies, they are more inclined to seek effective medications to alleviate their discomfort.
Moreover, key players in the industry more focus on research & development, and a rising number of clinical trials are helping to propel this market growth. For instance, in January 2024, UCB announced the randomized Phase III Study aims to assess the efficacy and safety of Xyzal (levocetirizine) compared to Zyrtec (cetirizine) in subjects suffering from dermatitis. This type of study is crucial in clinical research as it provides robust data on how well these medications perform in treating dermatitis, which is often characterized by inflammation, redness, and itching of the skin.
Restraints
Factors such as side effects & adverse reactions associated with the drugs, and stringent regulatory requirements, are expected to hamper the market.
Market Segment Analysis
The global cetirizine hydrochloride market is segmented based on dosage form, age group, application, distribution channels, and region.
The tablets segment accounted for approximately 64.3% of the global cetirizine hydrochloride market share
The tablets segment is expected to hold the largest market share over the forecast period. Cetirizine hydrochloride tablets are essential in the global market as a reliable treatment for various allergic conditions, such as allergic rhinitis, chronic urticaria, and allergic conjunctivitis. The increasing prevalence of allergies and growing awareness of effective allergy management strategies are anticipated to sustain the demand for cetirizine tablets over the forecast period.
In addition, key players in the industry strategies such as partnerships and collaborations are helping to propel this market growth. For instance, in August 2023, the National Medical Products Administration (NMPA) granted Xinhua Pharmaceutical (Gaomi) Co., Ltd., a wholly-owned subsidiary of Xinhua Pharmaceutical, the Approval Letter of Supplementary Application for Cetirizine Hydrochloride Tablets. This approval signifies that the product has successfully passed the quality and efficacy consistency evaluation required for generic drugs.
Market Geographical Share
North America accounted for approximately 43.9% of the global cetirizine hydrochloride market share
North America region is expected to hold the largest market share over the forecast period owing to the rise in allergic disorders, such as allergic rhinitis, chronic urticaria, and allergic conjunctivitis, which is a major factor propelling the demand for cetirizine hydrochloride in this region.
Allergic rhinitis, commonly known as hay fever, is a prevalent condition that affects a significant portion of the global population, with prevalence estimates ranging from 10% to 30%. In the United States, a substantial percentage of adults and children have reported experiencing seasonal allergies in recent years. According to data from the CDC, approximately 25.7% of U.S. adults and 18.9% of children stated they suffered from seasonal allergies in 2021.
This high prevalence of allergic rhinitis in the U.S. population creates a significant demand for antihistamine medications like cetirizine, which are effective in alleviating common symptoms associated with this condition, such as sneezing, runny nose, and itchy eyes. Moreover, growing public awareness of allergies and the treatment options accessible has led to a heightened demand for cetirizine.
Additionally, in this region, a major number of key player's presence, well-advanced healthcare infrastructure, and mergers & acquisitions are helping to propel this market growth in the region. For instance, in June 2022, Glenmark Pharmaceuticals Inc., USA, a fully owned subsidiary of Glenmark Pharmaceuticals Ltd., acquired the approved Abbreviated New Drug Applications (ANDAs) for several over-the-counter (OTC) drugs from Wockhardt Limited in the United States.
The acquired ANDAs include famotidine tablets USP, 10 mg and 20 mg (OTC) - used to treat and prevent ulcers in the stomach and intestine, cetirizine hydrochloride Tablets USP, 5 mg and 10 mg (OTC) - an antihistamine medication, and olopatadine hydrochloride ophthalmic solution USP, 0.1% (OTC) - indicated for allergic conjunctivitis and allergic rhinitis.
Market Segmentation
By Dosage Form
Tablets
Solutions
Syrups
By Age Group
Adult
Pediatric
By Applications
Allergic Rhinitis
Allergic Conjunctivitis
Chronic Urticaria
Eczema
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
The rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the cetirizine hydrochloride market include Johnson & Johnson Services, Inc., GSK plc, UCB S.A., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Major Pharmaceuticals, Cipla, Dr. Reddys Laboratories Ltd., AdvaCare Pharma, and Aden Healthcare among others.
Key Developments
In April 2023, Nicox SA announced that its exclusive partner in China, Ocumension Therapeutics, has submitted a New Drug Application (NDA) to obtain approval for the commercialization of Zerviate (cetirizine ophthalmic solution) at a concentration of 0.24%. This application is specifically for treating ocular itching associated with allergic conjunctivitis.
Why Purchase the Report?
To visualize the global cetirizine hydrochloride market segmentation based on dosage form, age group, application, distribution channels, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the cetirizine hydrochloride market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global cetirizine hydrochloride market report would provide approximately 70 tables, 63 figures, and 183 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Dosage Form
3.2. Snippet by Age Group
3.3. Snippet by Application
3.4. Snippet by Distribution Channels
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Allergic Diseases
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Side Effects and Adverse Reactions Associated with the Drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Dosage Form
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
6.1.2. Market Attractiveness Index, By Dosage Form
6.2. Tablet *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Solutions
6.4. Syrups
7. By Age Group
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
7.1.2. Market Attractiveness Index, By Age Group
7.2. Age Group*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Adult
7.4. Pediatric
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Allergic Rhinitis*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Allergic Conjunctivitis
8.4. Chronic Urticaria
8.5. Eczema
8.6. Others
9. By Distribution Channels
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.1.2. Market Attractiveness Index, By Distribution Channels
9.2. Hospital Pharmacies *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. U.K.
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Johnson & Johnson Services, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. GSK plc
12.3. UCB S.A.
12.4. Teva Pharmaceutical Industries Ltd.
12.5. Pfizer Inc.
12.6. Major Pharmaceuticals
12.7. Cipla
12.8. Dr. Reddys Laboratories Ltd.
12.9. AdvaCare Pharma
12.10. Aden Healthcare (*LIST NOT EXHAUSTIVE)
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Johnson & Johnson Services, Inc., 4.	Key Developments, GSK plc, UCB S.A., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Major Pharmaceuticals, Cipla, Dr. Reddys Laboratories Ltd., AdvaCare Pharma

표 목록 (Tables)

List of Tables

Table 1 Global Cetirizine Hydrochloride Market Value, By Dosage Form, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Cetirizine Hydrochloride Market Value, By Age Group, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Cetirizine Hydrochloride Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Cetirizine Hydrochloride Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Cetirizine Hydrochloride Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Cetirizine Hydrochloride Market Value, By Dosage Form, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Cetirizine Hydrochloride Market Value, By Dosage Form, 2022-2031 (US$ Million)

Table 8 Global Cetirizine Hydrochloride Market Value, By Age Group, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Cetirizine Hydrochloride Market Value, By Age Group, 2022-2031 (US$ Million)

Table 10 Global Cetirizine Hydrochloride Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 11 Global Cetirizine Hydrochloride Market Value, By Application, 2022-2031 (US$ Million)

Table 12 Global Cetirizine Hydrochloride Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 13 Global Cetirizine Hydrochloride Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 14 Global Cetirizine Hydrochloride Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 15 Global Cetirizine Hydrochloride Market Value, By Region, 2022-2031 (US$ Million)

Table 16 North America Cetirizine Hydrochloride Market Value, By Dosage Form, 2022-2031 (US$ Million)

Table 17 North America Cetirizine Hydrochloride Market Value, By Age Group, 2022-2031 (US$ Million)

Table 18 North America Cetirizine Hydrochloride Market Value, By Application, 2022-2031 (US$ Million)

Table 19 North America Cetirizine Hydrochloride Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 North America Cetirizine Hydrochloride Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Asia-Pacific Cetirizine Hydrochloride Market Value, By Dosage Form, 2022-2031 (US$ Million)

Table 22 Asia-Pacific Cetirizine Hydrochloride Market Value, By Age Group, 2022-2031 (US$ Million)

Table 23 Asia-Pacific Cetirizine Hydrochloride Market Value, By Application, 2022-2031 (US$ Million)

Table 24 Asia-Pacific Cetirizine Hydrochloride Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Cetirizine Hydrochloride Market Value, By Country, 2022-2031 (US$ Million)

Table 26 Europe Cetirizine Hydrochloride Market Value, By Dosage Form, 2022-2031 (US$ Million)

Table 27 Europe Cetirizine Hydrochloride Market Value, By Age Group, 2022-2031 (US$ Million)

Table 28 Europe Cetirizine Hydrochloride Market Value, By Application, 2022-2031 (US$ Million)

Table 29 Europe Cetirizine Hydrochloride Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 30 Europe Cetirizine Hydrochloride Market Value, By Country, 2022-2031 (US$ Million)

Table 31 South America Cetirizine Hydrochloride Market Value, By Dosage Form, 2022-2031 (US$ Million)

Table 32 South America Cetirizine Hydrochloride Market Value, By Age Group, 2022-2031 (US$ Million)

Table 33 South America Cetirizine Hydrochloride Market Value, By Application, 2022-2031 (US$ Million)

Table 34 South America Cetirizine Hydrochloride Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 35 South America Cetirizine Hydrochloride Market Value, By Country, 2022-2031 (US$ Million)

Table 36 Middle East and Africa Cetirizine Hydrochloride Market Value, By Dosage Form, 2022-2031 (US$ Million)

Table 37 Middle East and Africa Cetirizine Hydrochloride Market Value, By Age Group, 2022-2031 (US$ Million)

Table 38 Middle East and Africa Cetirizine Hydrochloride Market Value, By Application, 2022-2031 (US$ Million)

Table 39 Middle East and Africa Cetirizine Hydrochloride Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 40 Middle East and Africa Cetirizine Hydrochloride Market Value, By Country, 2022-2031 (US$ Million)

Table 41 Johnson & Johnson Services, Inc.: Overview

Table 42 Johnson & Johnson Services, Inc.: Product Portfolio

Table 43 Johnson & Johnson Services, Inc.: Key Developments

Table 44 GSK plc: Overview

Table 45 GSK plc: Product Portfolio

Table 46 GSK plc: Key Developments

Table 47 UCB S.A.: Overview

Table 48 UCB S.A.: Product Portfolio

Table 49 UCB S.A.: Key Developments

Table 50 Teva Pharmaceutical Industries Ltd.: Overview

Table 51 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 52 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 53 Pfizer Inc.: Overview

Table 54 Pfizer Inc.: Product Portfolio

Table 55 Pfizer Inc.: Key Developments

Table 56 Major Pharmaceuticals: Overview

Table 57 Major Pharmaceuticals: Product Portfolio

Table 58 Major Pharmaceuticals: Key Developments

Table 59 Cipla: Overview

Table 60 Cipla: Product Portfolio

Table 61 Cipla: Key Developments

Table 62 Dr. Reddys Laboratories Ltd.: Overview

Table 63 Dr. Reddys Laboratories Ltd.: Product Portfolio

Table 64 Dr. Reddys Laboratories Ltd.: Key Developments

Table 65 AdvaCare Pharma: Overview

Table 66 AdvaCare Pharma: Product Portfolio

Table 67 AdvaCare Pharma: Key Developments

Table 68 Aden Healthcare: Overview

Table 69 Aden Healthcare: Product Portfolio

Table 70 Aden Healthcare: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 2 Global Cetirizine Hydrochloride Market Share, By Dosage Form, 2023 & 2031 (%)

Figure 3 Global Cetirizine Hydrochloride Market Share, By Age Group, 2023 & 2031 (%)

Figure 4 Global Cetirizine Hydrochloride Market Share, By Application, 2023 & 2031 (%)

Figure 5 Global Cetirizine Hydrochloride Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 6 Global Cetirizine Hydrochloride Market Share, By Region, 2023 & 2031 (%)

Figure 7 Global Cetirizine Hydrochloride Market Y-o-Y Growth, By Dosage Form, 2023-2031 (%)

Figure 8 Tablets Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 9 Solutions Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 10 Syrups Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 11 Global Cetirizine Hydrochloride Market Y-o-Y Growth, By Age Group, 2023-2031 (%)

Figure 12 Adult Age Group in Global Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 13 Pediatric Age Group in Global Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 14 Global Cetirizine Hydrochloride Market Y-o-Y Growth, By Application, 2023-2031 (%)

Figure 15 Allergic Rhinitis Application in Global Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 16 Allergic Conjunctivitis Application in Global Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 17 Chronic Urticaria Application in Global Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 18 Eczema Application in Global Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 19 Others Application in Global Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 20 Global Cetirizine Hydrochloride Market Y-o-Y Growth, By Distribution Channel, 2023-2031 (%)

Figure 21 Hospital Pharmacies Distribution Channel in Global Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 22 Retail Pharmacies Distribution Channel in Global Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 23 Online Pharmacies Distribution Channel in Global Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 24 Global Cetirizine Hydrochloride Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 25 North America Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 26 North America Cetirizine Hydrochloride Market Share, By Dosage Form, 2023 & 2031 (%)

Figure 27 North America Cetirizine Hydrochloride Market Share, By Age Group, 2023 & 2031 (%)

Figure 28 North America Cetirizine Hydrochloride Market Share, By Application, 2023 & 2031 (%)

Figure 29 North America Cetirizine Hydrochloride Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 30 North America Cetirizine Hydrochloride Market Share, By Country, 2023 & 2031 (%)

Figure 31 Asia-Pacific Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 32 Asia-Pacific Cetirizine Hydrochloride Market Share, By Dosage Form, 2023 & 2031 (%)

Figure 33 Asia-Pacific Cetirizine Hydrochloride Market Share, By Age Group, 2023 & 2031 (%)

Figure 34 Asia-Pacific Cetirizine Hydrochloride Market Share, By Application, 2023 & 2031 (%)

Figure 35 Asia-Pacific Cetirizine Hydrochloride Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 36 Asia-Pacific Cetirizine Hydrochloride Market Share, By Country, 2023 & 2031 (%)

Figure 37 Europe Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 38 Europe Cetirizine Hydrochloride Market Share, By Dosage Form, 2023 & 2031 (%)

Figure 39 Europe Cetirizine Hydrochloride Market Share, By Age Group, 2023 & 2031 (%)

Figure 40 Europe Cetirizine Hydrochloride Market Share, By Application, 2023 & 2031 (%)

Figure 41 Europe Cetirizine Hydrochloride Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 42 Europe Cetirizine Hydrochloride Market Share, By Country, 2023 & 2031 (%)

Figure 43 South America Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 44 South America Cetirizine Hydrochloride Market Share, By Dosage Form, 2023 & 2031 (%)

Figure 45 South America Cetirizine Hydrochloride Market Share, By Age Group, 2023 & 2031 (%)

Figure 46 South America Cetirizine Hydrochloride Market Share, By Application, 2023 & 2031 (%)

Figure 47 South America Cetirizine Hydrochloride Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 48 South America Cetirizine Hydrochloride Market Share, By Country, 2023 & 2031 (%)

Figure 49 Middle East and Africa Cetirizine Hydrochloride Market Value, 2022-2031 (US$ Million)

Figure 50 Middle East and Africa Cetirizine Hydrochloride Market Share, By Dosage Form, 2023 & 2031 (%)

Figure 51 Middle East and Africa Cetirizine Hydrochloride Market Share, By Age Group, 2023 & 2031 (%)

Figure 52 Middle East and Africa Cetirizine Hydrochloride Market Share, By Application, 2023 & 2031 (%)

Figure 53 Middle East and Africa Cetirizine Hydrochloride Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 54 Johnson & Johnson Services, Inc.: Financials

Figure 55 GSK plc: Financials

Figure 56 UCB S.A.: Financials

Figure 57 Teva Pharmaceutical Industries Ltd.: Financials

Figure 58 Pfizer Inc.: Financials

Figure 59 Major Pharmaceuticals: Financials

Figure 60 Cipla: Financials

Figure 61 Dr. Reddys Laboratories Ltd.: Financials

Figure 62 AdvaCare Pharma: Financials

Figure 63 Aden Healthcare: Financials

세계 세티리진 염산염 시장 – 2024-2031년

Global Cetirizine Hydrochloride Market - 2024-2031